Ionis reports second quarter 2020 financial results and recent business achievements
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Ionis Pharmaceuticals (IONS) Tops Q2 EPS by 4c
August 5, 2020 7:15 AM EDTIonis Pharmaceuticals (NASDAQ: IONS) reported Q2 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $146 million versus the consensus estimate of $148.87 million.
Second Quarter 2020 Financial Results and Highlights
On track to achieve financial guidance of being meaningfully profitable this yearNet income of $8 million on a non-GAAP basis and a net loss of $32 million on a GAAP basisAchieved quarter over quarter growth in commercial and R&D revenuesCommercial revenue from SPINRAZA® (nusinersen) royalties increased to $72... More